AKT1 is altered in 1.06% of osteosarcoma patients [2].

AKT1 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AKT2 is altered in 2.36% of osteosarcoma patients [2].

AKT2 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AKT3 is altered in 0.82% of osteosarcoma patients [2].

AKT3 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ARID1A is altered in 0.78% of osteosarcoma patients [2].

ARID1A is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ATM is altered in 2.42% of osteosarcoma patients [2].

ATM is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain ATM status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

ATR is altered in 1.61% of osteosarcoma patients [2].

ATR is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain ATR status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

ATRX is altered in 10.63% of osteosarcoma patients [2].

ATRX is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ATRX status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

AXL is altered in 1.17% of osteosarcoma patients [2].

AXL is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains AXL status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BARD1 is altered in 0.44% of osteosarcoma patients [2].

BARD1 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain BARD1 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

BRCA1 is altered in 1.61% of osteosarcoma patients [2].

BRCA1 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

BRCA2 is altered in 2.75% of osteosarcoma patients [2].

BRCA2 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

BRIP1 is altered in 1.59% of osteosarcoma patients [2].

BRIP1 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain BRIP1 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

CCND1 is altered in 2.37% of osteosarcoma patients [2].

CCND1 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCND2 is altered in 1.19% of osteosarcoma patients [2].

CCND2 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND2 status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCND3 is altered in 12.45% of osteosarcoma patients [2].

CCND3 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND3 status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCNE1 is altered in 8.37% of osteosarcoma patients [2].

CCNE1 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCNE1 status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK12 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain CDK12 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

CDK4 is altered in 8.27% of osteosarcoma patients [2].

CDK4 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK6 is altered in 1.2% of osteosarcoma patients [2].

CDK6 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDKN2A is altered in 16.38% of osteosarcoma patients [2].

CDKN2A is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CHEK1 is altered in 0.86% of osteosarcoma patients [2].

CHEK1 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain CHEK1 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

CHEK2 is altered in 0.79% of osteosarcoma patients [2].

CHEK2 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain CHEK2 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

CRKL is altered in 0.84% of osteosarcoma patients [2].

CRKL is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERBB2 is altered in 0.69% of osteosarcoma patients [2].

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EWSR1 is altered in 0.81% of osteosarcoma patients [2].

EWSR1 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains EWSR1 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCA is altered in 1.61% of osteosarcoma patients [2].

FANCA is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain FANCA status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

FANCB is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain FANCB status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

FANCC is altered in 0.81% of osteosarcoma patients [2].

FANCC is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain FANCC status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

FANCD2 is altered in 4.26% of osteosarcoma patients [2].

FANCD2 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain FANCD2 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

FANCE is altered in 3.12% of osteosarcoma patients [2].

FANCE is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain FANCE status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

FANCF is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain FANCF status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

FANCG is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain FANCG status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

FANCI is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain FANCI status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

FANCL is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain FANCL status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

FANCM is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain FANCM status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

FBXW7 is altered in 1.42% of osteosarcoma patients [2].

FBXW7 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains FBXW7 status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FUS is altered in 0.43% of osteosarcoma patients [2].

FUS is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains FUS status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain MCPH1 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MET is altered in 0.69% of osteosarcoma patients [2].

MET is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MRE11A is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain MRE11A status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MTOR is altered in 1.98% of osteosarcoma patients [2].

MTOR is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MYC is altered in 6.64% of osteosarcoma patients [2].

MYC is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MYCN is altered in 0.79% of osteosarcoma patients [2].

MYCN is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain MYCN status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

NBN is altered in 1.63% of osteosarcoma patients [2].

NBN is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain NBN status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

PALB2 is altered in 0.79% of osteosarcoma patients [2].

PALB2 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain PALB2 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

PDGFRA is altered in 6.29% of osteosarcoma patients [2].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3CA is altered in 2.07% of osteosarcoma patients [2].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3CG is altered in 1.4% of osteosarcoma patients [2].

PIK3CG is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PTEN is altered in 3.82% of osteosarcoma patients [2].

PTEN is an inclusion eligibility criterion in 3 clinical trials for osteosarcoma, of which 3 are open and 0 are closed. Of the trials that contain PTEN status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

RAD50 is altered in 0.43% of osteosarcoma patients [2].

RAD50 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain RAD50 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

RAD51 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

RAD51B is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51B status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

RAD51C is altered in 1.79% of osteosarcoma patients [2].

RAD51C is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51C status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

RAD51D is altered in 0.45% of osteosarcoma patients [2].

RAD51D is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51D status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

RAD54L is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain RAD54L status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

RET is altered in 1.39% of osteosarcoma patients [2].

RET is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RICTOR is altered in 1.76% of osteosarcoma patients [2].

RICTOR is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RICTOR status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RPTOR is altered in 3.08% of osteosarcoma patients [2].

RPTOR is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SDHA is altered in 2.22% of osteosarcoma patients [2].

SDHA is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains SDHA status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SDHAF2 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains SDHAF2 status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SDHB is altered in 0.42% of osteosarcoma patients [2].

SDHB is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains SDHB status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SDHC is altered in 2.58% of osteosarcoma patients [2].

SDHC is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains SDHC status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SDHD is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains SDHD status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SLX4 is altered in 2.08% of osteosarcoma patients [2].

SLX4 is an inclusion eligibility criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain SLX4 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

TSC1 is altered in 1.94% of osteosarcoma patients [2].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TSC2 is altered in 2.31% of osteosarcoma patients [2].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].